Monitoring Serum Protein Electrophoresis in Chronic Inflammatory Diseases

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Serial serum protein electrophoresis (SPE) quantifies the humoral immune response over time, providing objective data on disease trajectory and treatment efficacy in chronic inflammatory or neoplastic conditions in dogs and cats. Rising total globulins with falling albumin suggests ongoing antigenic stimulation, while a progressive increase in gamma globulins over months indicates persistent inflammation or neoplasia.
• A polyclonal gammopathy, characterized by a broad, dome-shaped elevation in the gamma region, reflects polyclonal B-cell expansion due to persistent antigenic stimulation from conditions like ehrlichiosis, leishmaniasis, or feline infectious peritonitis. Serial monitoring tracks the trajectory of this response and serves as an objective endpoint for treatment trials.
• A monoclonal spike, a narrow and tall peak in the gamma or beta region, signifies a monoclonal gammopathy, most often indicative of multiple myeloma or B-cell lymphoma. A doubling of the M-spike height or an increase of over 1 g/dL warrants investigation for progressive disease and reconsideration of therapy.
• The transition from a polyclonal to a monoclonal pattern during monitoring is a critical indicator of neoplastic transformation, necessitating bone marrow evaluation and urine protein electrophoresis to detect Bence Jones proteinuria.
• Method consistency is paramount; serial SPE samples must be analyzed by the same laboratory using the same platform (e.g., agarose gel vs. capillary electrophoresis) to ensure accurate trend interpretation and avoid artefactual shifts in protein fractions.
• The albumin to globulin ratio serves as a sensitive composite index, with a falling ratio correlating with chronicity and poorer prognosis in inflammatory states due to decreased albumin synthesis and potential protein loss.

Serial serum protein electrophoresis (SPE) provides a quantitative window into the humoral immune response over time. For the practicing veterinarian managing chronic inflammatory or neoplastic disease in dogs and cats, repeated SPE offers objective data on disease trajectory, treatment response, and emerging complications such as monoclonal gammopathy. This article addresses the interpretation of serial SPE trends, the distinction between reactive and neoplastic globulin patterns, and the practical decisions that follow from changes between samples. It assumes the reader has already established a diagnosis and seeks guidance on longitudinal monitoring instead of initial workup.

The clinical question this article answers is direct: when a patient with a known inflammatory or neoplastic condition returns for reassessment, what does a change in the electrophoretic pattern mean, and what action should follow? Serial SPE is not a screening test. It is a monitoring tool whose value depends on a stable laboratory method, a clear baseline, and an understanding of the biologic half-lives and production dynamics of the proteins being measured. The sections that follow build the physiologic foundation, then move to pattern recognition, sampling strategy, and clinical decision frameworks.

At a Glance

Physiologic Basis of Serial Electrophoretic Monitoring

Serum proteins separate into albumin, alpha, beta, and gamma fractions based on their migration in an electric field. The gamma region consists almost entirely of immunoglobulins produced by plasma cells. In chronic inflammation, persistent antigenic stimulation drives polyclonal B-cell expansion, producing a broad elevation of the gamma fraction. The magnitude and shape of that elevation reflect the intensity and duration of the stimulus.

Immunoglobulin production is not static. The serum concentration at any time represents the balance between synthesis and catabolism, with IgG half-life in dogs approximating 8 to 17 days depending on the subclass. This kinetic reality means that changes in the electrophoretic pattern lag behind changes in the underlying disease process by days to weeks. A patient whose inflammation has resolved will show a gradual decline in gamma globulins over several weeks, not an immediate normalization. Conversely, a rising gamma fraction on two samples taken 3 to 4 weeks apart indicates ongoing or increasing antigenic stimulation.

Albumin behaves as the inverse marker. As a negative acute phase protein, albumin synthesis falls during chronic inflammation, and its concentration declines as globulins rise. The albumin to globulin ratio therefore compresses both trends into a single number that often tracks disease severity more sensitively than either fraction alone. The 2004 ACVIM consensus statement on proteinuria in dogs and cats emphasizes that persistent protein loss, including the loss of albumin, identifies patients at increased risk for adverse outcomes, and serial monitoring of protein status is central to that assessment ACVIM consensus statement on proteinuria assessment and management.

The Polyclonal Pattern in Chronic Inflammation

A polyclonal gammopathy appears on SPE as a broad, dome-shaped elevation of the gamma region. The pattern reflects the contribution of many different immunoglobulin clones responding to multiple epitopes. In dogs, common causes include ehrlichiosis, leishmaniasis, and chronic pyoderma. In cats, feline infectious peritonitis and chronic cholangiohepatitis produce characteriztic patterns, often with prominent beta-gamma bridging.

Serial monitoring of a polyclonal pattern serves three purposes. First, it quantifies the trajectory of the inflammatory response. A patient whose gamma globulins rise from 2.5 g/dL to 4.0 g/dL over three months is not stable, even if clinical signs are subtle. Second, it provides an objective endpoint for treatment trials. A glucocorticoid-responsive inflammatory disease should show a measurable decline in gamma globulins within 4 to 6 weeks of effective immunosuppressive therapy. Failure of the gamma fraction to fall despite clinical improvement should prompt reconsideration of the diagnosis. Third, serial SPE can detect transformation from a polyclonal to an oligoclonal or monoclonal pattern, which occurs in some chronic infections and lymphoid neoplasms.

Monoclonal Gammopathy and the Transition From Reactive to Neoplastic

A narrow, tall spike within the gamma or beta region indicates a monoclonal gammopathy, the product of a single plasma cell clone. In dogs and cats, this pattern most often signals multiple myeloma, but it can also accompany B-cell lymphoma, chronic lymphocytic leukemia, or, rarely, benign monoclonal gammopathy of undetermined significance. The distinction matters because the monitoring interval and treatment threshold differ substantially between these entities.

Serial SPE is the single most useful test for tracking a known monoclonal gammopathy. The height of the M-spike correlates with tumor burden in most cases, and a rising spike on consecutive samples indicates progressive disease. A doubling of the spike height, or an increase of more than 1 g/dL between samples, warrants restaging and reconsideration of therapy. Conversely, a falling spike after chemotherapy or prednisolone initiation suggests a response, though the nadir may lag behind clinical improvement by several weeks.

The transition from polyclonal to monoclonal pattern during monitoring of a chronic inflammatory disease is an important failure mode. This change should trigger bone marrow evaluation and urine protein electrophoresis to detect Bence Jones proteinuria. The same laboratory standards that govern initial interpretation apply to serial samples, and the American Society for Veterinary Clinical Pathology provides guidance on method validation and quality assurance that supports reliable longitudinal comparison ASVCP quality assurance and laboratory standards guidelines.

Sampling Intervals and Method Consistency

The interval between serial samples should be matched to the kinetics of the disease and the half-life of the dominant immunoglobulin. For acute treatment monitoring, such as induction chemotherapy for myeloma, samples every 2 to 3 weeks capture the expected decline in the M-spike. For chronic inflammatory disease under stable therapy, sampling every 6 to 8 weeks is usually sufficient to detect meaningful trends without excessive cost. Once a patient is stable for 6 months, intervals can extend to every 3 to 4 months.

Method consistency is non-negotiable. Agarose gel electrophoresis and capillary electrophoresis produce different fraction boundaries, and reference intervals differ between platforms. Serial samples should be analyzed by the same laboratory using the same method. If a laboratory changes its platform, a new baseline should be established with a paired sample run on both systems. The ASVCP guidelines emphasize that reference intervals are method-specific and that laboratories must validate any change in methodology before clinical use ASVCP quality assurance and laboratory standards guidelines.

Serial Electrophoresis as a Monitoring Tool

Serial protein electrophoresis provides a quantitative framework for tracking disease trajectory that routine biochemistry cannot match. The value lies not in a single result but in the direction and magnitude of change between samples. For the practicing veterinarian, the central question is whether the pattern is stable, improving, or progressing, and each of those answers carries different therapeutic implications.

The first decision point occurs when a baseline electrophoretic abnormality is identified. Before committing to a monitoring schedule, confirm that the abnormality is real and reproducible. This requires attention to method consistency. Agarose gel electrophoresis and capillary zone electrophoresis can produce different absolute values for the same sample, and even within a single laboratory, inter-run variation exists. The ASVCP quality assurance guidelines emphasize that reference intervals and method validation are laboratory-specific, and serial comparisons are only valid when the same method and laboratory are used throughout the monitoring period. If a patient must be switched from one laboratory to another, obtain a new baseline instead of interpreting the first post-switch result as a change in disease status.

Defining the Monitoring Interval

The appropriate sampling interval depends on the underlying disease, the speed of expected change, and the clinical question being asked. For chronic inflammatory conditions such as feline infectious peritonitis, ehrlichiosis, or immune-mediated polyarthritis, the electrophoretic pattern changes slowly. A reasonable starting point is re-evaluation at 4 to 6 weeks after initiating or changing therapy, then at 8 to 12 week intervals once a trend is established. This aligns with the observation from serial biomarker studies in other disciplines that the rate of change, not the absolute value, carries the most prognostic information. The systematic review of serial serum protein biomarkers in human traumatic brain injury demonstrated that the "effective half-life" of a protein in serum, that is, the rate at which it falls after the inciting stimulus resolves, is a useful concept for interpreting serial measurements. The same logic applies to globulins in chronic inflammation: a slow fall after therapy begins suggests a gradual reduction in antigenic stimulation, whereas a rapid fall may indicate a different mechanism entirely, such as protein-losing enteropathy or hemodilution.

For monoclonal gammopathies, the interval should be shorter. Once a monoclonal spike is confirmed, repeat electrophoresis at 2 to 4 week intervals during the initial staging period to establish whether the spike is stable, slowly progressive, or rapidly expanding. A doubling of the spike height over 4 to 6 weeks is concerning for an aggressive neoplastic process and should prompt bone marrow evaluation and staging. A stable spike over 3 to 6 months in an asymptomatic patient supports a diagnosis of monoclonal gammopathy of undetermined significance, though this entity is less well characterized in dogs and cats than in humans.

Interpreting Changes in the Polyclonal Pattern

The polyclonal pattern in chronic inflammation is characterized by a broad, symmetric increase in the beta and gamma fractions. Serial monitoring focuses on three parameters: total globulin concentration, the height and width of the polyclonal peak, and the albumin to globulin ratio.

A falling total globulin concentration with a narrowing peak width suggests resolving inflammation. This is the expected response to effective therapy in conditions such as ehrlichiosis, leishmaniasis, and feline infectious peritonitis. The albumin to globulin ratio is a useful composite index because albumin tends to fall during active inflammation and recover as the inflammatory stimulus resolves. A rising albumin with a falling globulin fraction is a favourable trend even when the absolute globulin value remains above the reference interval.

A rising polyclonal peak despite therapy indicates inadequate antigenic control. This should prompt reconsideration of the diagnosis, the drug protocol, or the presence of a concurrent inflammatory or neoplastic process. In endemic regions, co-infection with multiple vector-borne pathogens can produce a rising polyclonal gammopathy even when the primary disease appears controlled.

A change in peak morphology is a critical finding. A broad polyclonal peak that develops a narrow, tall spike within it suggests the emergence of a monoclonal population. This transition, from polyclonal to monoclonal, is the electrophoretic signature of progression from reactive plasmacytosis to plasma cell neoplasia. The MSD Veterinary Manual describes monoclonal gammopathies as most commonly associated with multiple myeloma and other plasma cell tumors in dogs and cats, and the development of a monoclonal spike in a patient previously showing only polyclonal hyperglobulinaemia warrants aggressive diagnostic investigation.

Monitoring Parameters and Their Clinical Significance

Documenting the Electrophoretic Pattern

Serial monitoring is only as useful as the record keeping that supports it. Each electrophoretic report should be filed with the patient record, and the following data should be extracted into a dedicated monitoring table: date, laboratory, method, total protein, albumin, alpha, beta, and gamma fractions, albumin to globulin ratio, and a qualitative description of peak morphology. This table allows rapid visual assessment of trends without re-reading each report.

When a patient changes laboratories, note this in the record and flag the first post-switch result as a potential method artefact. The ASVCP guidelines recommend that laboratories provide method-specific reference intervals, and clinicians should verify that the new laboratory's intervals are appropriate for the species and method before interpreting results.

Species and Clinical Context Modifications

Dogs and cats differ in their typical electrophoretic responses to chronic inflammation. Cats with feline infectious peritonitis frequently show a marked polyclonal gammopathy with beta-gamma bridging, and serial electrophoresis is a useful adjunct to monitoring response to antiviral or immunomodulatory therapy. Dogs with ehrlichiosis typically show a polyclonal gammopathy that may persist for months after successful treatment, so a slow fall in globulins should not be interpreted as treatment failure.

The patient's clinical status should always be interpreted alongside the electrophoretic trend. A stable or falling globulin concentration in a patient with worsening clinical signs should prompt investigation for non-humoral causes of deterioration, such as protein-losing nephropathy or enteropathy. The ACVIM consensus statement on proteinuria notes that persistent renal proteinuria identifies patients at increased risk for adverse outcomes, and concurrent proteinuria can confound interpretation of the albumin fraction in serial electrophoresis. A falling albumin with a stable globulin concentration may reflect urinary protein loss instead of improving inflammation, and urine protein to creatinine ratio should be assessed in any patient with a declining albumin fraction.

In production animals, the indications for serial electrophoresis differ. The consensus recommendations on passive immunity in dairy calves describe serum total protein measurement as a practical proxy for immunoglobulin G in the first week of life, but serial electrophoresis has limited application in herd-level monitoring. The cost and turnaround time are prohibitive for routine use, and total protein or immunoglobulin G measurement provides adequate information for colostrum management decisions.

Recognized Complications and Failure Modes

Serial electrophoresis fails as a monitoring tool when the laboratory method changes between samples, when the patient's acute-phase response confounds interpretation, or when the clinician misclassifies the pattern. Each failure mode has a characteriztic signature.

Method drift is the most insidious. A patient monitored across 12 months may have samples analyzed on different analyzers, different gel lots, or in different laboratories. The resulting shifts in absolute globulin concentrations can mimic disease progression or response. The ASVCP quality assurance guidelines emphasize that reference intervals and method validation are laboratory-specific, and this principle extends to serial monitoring. The corrective action is to request that all serial samples for a given patient be analyzed by the same laboratory, ideally on the same platform, and to record the laboratory and method on each submission.

Acute-phase interference produces a transient polyclonal increase that can be mistaken for worsening inflammation. Albumin decreases while alpha and beta globulins rise, creating a pattern that overlaps with chronic inflammatory disease. The discriminating feature is time course. Acute-phase changes evolve over days, whereas chronic inflammatory patterns evolve over weeks to months. A rising globulin concentration with a stable albumin and a clinically stable patient should prompt a repeat sample in 2 to 4 weeks instead of an immediate treatment change.

Hypogammaglobulinaemia as a treatment effect is under-recognized. Immunosuppressive therapy, particularly glucocorticoids and other lymphocyte-depleting agents, can lower immunoglobulin production. A falling gamma globulin fraction in a patient whose clinical signs are improving may represent therapeutic response, but in a patient who is deteriorating it may indicate excessive immunosuppression and increased infection risk. The MSD Veterinary Manual notes that glucocorticoid effects on protein metabolism are dose-dependent and can include decreased immunoglobulin concentrations, so the globulin trend must be interpreted alongside the clinical trajectory, not in isolation.

Common Errors in Interpretation

Less experienced clinicians frequently over-interpret small changes. A 2 to 3 g/L change in gamma globulin between samples is often within analytic and biologic variation, particularly when the samples were run on different days or in different batches. The corrective action is to establish a threshold for meaningful change before starting serial monitoring, typically a 20 to 25 percent change from baseline, and to confirm any apparent trend with a third sample before altering therapy.

A second error is treating the electrophoretic pattern as diagnostic instead of supportive. The pattern narrows the differential list, but it does not identify the underlying disease. A persistent polyclonal gammopathy in a cat with weight loss and anorexia justifies investigation for feline infectious peritonitis, multiple myeloma, or lymphoma, but the electrophoresis alone cannot distinguish these. The ACVIM consensus statement on proteinuria makes the analogous point that proteinuria must be localized and characterized before it can guide management, and the same reasoning applies to gammopathy.

A third error is neglecting the albumin fraction. Serial monitoring that tracks only globulins misses the prognostic value of a falling albumin. Hypoalbuminaemia in chronic inflammation reflects both decreased synthesis and increased losses, and it carries independent prognostic weight. The monitoring protocol should track albumin and globulin together, and a falling albumin with a stable globulin should trigger investigation for protein-losing enteropathy or nephropathy.

Limitations of the Current Evidence

The evidence base for serial electrophoresis in companion animals is largely extrapolated from human medicine and from cross-sectional veterinary studies. There are no prospective veterinary trials that define optimal sampling intervals, threshold changes that predict relapse, or the comparative value of electrophoresis versus serial globulin measurement alone. The systematic review of serial protein biomarker sampling in human traumatic brain injury illustrates the general principle that serial biomarker dynamics carry information beyond single measurements, but it also demonstrates how much methodologic work is required to establish half-lives and sampling windows, work that has not been done for canine and feline globulin fractions.

Expert opinion differs on the value of routine repeat electrophoresis in stable patients. Some clinicians repeat electrophoresis at every recheck, while others reserve it for clinical deterioration or for suspected transformation from polyclonal to monoclonal disease. The more conservative approach is reasonable when the clinical examination and a serum total protein with albumin are stable, because the additional information from electrophoresis is unlikely to change management.

Referral and Escalation Criteria

Referral to a specialist is warranted when a monoclonal gammopathy is confirmed, when a previously polyclonal pattern converts to monoclonal, or when the globulin concentration rises despite apparently adequate treatment. These situations require bone marrow evaluation, immunofixation, and staging that are best performed by an internal medicine specialist or oncologist.

Laboratory consultation is appropriate when the electrophoretic pattern is atypical, when there is a discrepancy between the total protein and the electrophoretic fractions, or when the laboratory reports a pattern that does not match the clinical picture. Clinical pathologists can review the gel, confirm or refute the automated interpretation, and recommend additional testing such as immunofixation or urine electrophoresis.

Regulatory reporting is rarely triggered by electrophoresis results themselves. However, if the underlying disease is a notifiable infectious condition, such as chronic brucellosis in a breeding kennel, the WOAH terrestrial animal health standards and local veterinary authorities define the reporting obligations. The AVMA practice resources provide guidance on professional obligations in these circumstances, and the clinician should confirm regional requirements before acting.

Frequently Asked Questions

How Often Should I Repeat Electrophoresis When the Clinical Picture Is Stable?

For a stable patient with a known inflammatory or neoplastic process, repeat electrophoresis at 8 to 12 week intervals is a reasonable default. This interval captures meaningful changes in globulin production without generating excessive cost. If the patient is receiving treatment that is expected to alter the underlying disease, consider sampling at the anticipated nadir of response, typically 2 to 4 weeks after a therapeutic change. When the clinical picture deteriorates, sample immediately instead of waiting for the scheduled interval. The ASVCP quality assurance and laboratory standards guidance emphasizes that serial comparisons are only valid when the same laboratory and method are used throughout.

What Can I Do When the Reference Laboratory Cannot Provide Electrophoresis?

When protein electrophoresis is unavailable, total protein and albumin measurements from a biochemistry panel provide a crude substitute. Calculate the globulin fraction by subtracting albumin from total protein. A rising globulin fraction with a falling albumin fraction suggests ongoing inflammation or neoplasia, but this approach cannot distinguish polyclonal from monoclonal patterns. Serum viscosity, if the laboratory offers it, can flag marked hyperglobulinemia. Consider whether a different commercial laboratory offers electrophoresis as a mail-in service, since many regional laboratories accept refrigerated serum samples. The MSD Veterinary Manual professional reference lists alternative protein assessment methods that may be available locally.

How Do I Explain Serial Electrophoresis to an Owner Who Is Concerned About Cost?

Frame electrophoresis as a monitoring tool that can detect treatment failure earlier than clinical signs alone. Explain that a single test provides a snapshot, while serial testing shows whether the abnormal protein is increasing, decreasing, or holding steady. Offer a concrete plan, such as three tests at defined intervals, and state what action each possible result would trigger. This transparency helps owners see the test as part of a decision pathway instead of an open-ended expense. The AVMA practice resources include guidance on communicating cost-benefit reasoning to clients in a way that preserves trust and informed consent.

Does the Monitoring Approach Differ Between Dogs and Cats?

Yes. Cats with chronic inflammation, particularly those with cholangitis or inflammatory bowel disease, frequently develop a polyclonal gammopathy that can be dramatic. Cats also show a higher prevalence of monoclonal gammopathies associated with myeloma-related disorders. Dogs more commonly present with monoclonal gammopathies from B-cell neoplasia, and their polyclonal responses tend to be more moderate. In both species, the same interpretive framework applies, but the pretest probability of an underlying neoplastic process differs. The ACVIM consensus statement on proteinuria assessment notes that species-specific reference intervals and disease prevalence should inform interpretation of serial protein measurements.

What Records Should I Keep for Longitudinal Comparison?

Maintain a dedicated table in the medical record listing the date, laboratory, method, total protein, albumin, globulin fractions, and the electrophoretic tracing or scanned image. Record the interpretation verbatim from the laboratory report, including any comments about the pattern. Note the clinical status, current medications, and any intercurrent illness at the time of sampling, since these can affect globulin concentrations. Store the original laboratory report in the patient file and keep a summary table in the problem list. This structure allows rapid comparison at each revisit and prevents reliance on memory. The ASVCP quality assurance and laboratory standards guidance recommends documenting method changes because switching laboratories invalidates direct comparison.

When Should I Escalate From Monitoring to a More Aggressive Diagnostic Workup?

Escalate when serial electrophoresis shows a rising monoclonal spike despite treatment, a polyclonal pattern that transitions to a monoclonal pattern, or a progressive increase in the gamma fraction accompanied by worsening hypoalbuminemia. A doubling of the monoclonal spike over two consecutive samplings warrants bone marrow evaluation and imaging. Similarly, new hypercalcemia, lytic bone lesions, or unexplained bleeding should trigger immediate investigation instead of continued monitoring. The WOAH terrestrial animal health standards are not directly applicable to companion animal oncology, but they illustrate the principle that surveillance protocols should have predefined escalation thresholds. Define these thresholds at the start of monitoring so that decisions are made prospectively, not reactively.

Related Clinical & Scientific Guides

• Peripheral Blood Smear Evaluation: A Step-by-Step Guide
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation

References and Further Reading

• Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal).. 2005.
• Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review.. 2017.
• Consensus recommendations on calf- and herd-level passive immunity in dairy calves in the United States.. 2020.
• Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder.. 2017.
• Protein binding in antiretroviral therapies.. 2003.
• Serum transaminase elevations as indicators of hepatic injury following the administration of drugs.. 1998.
• American Society for Veterinary Clinical Pathology Guidelines. American Society for Veterinary Clinical Pathology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Monitoring Inflammatory Markers in Chronic Enteropathy
• Monitoring Serum Lactate in Critically Ill Veterinary Patients
• Monitoring Serum Bile Acids for Hepatobiliary Disease Management
• Monitoring Renal Function in Chronic Kidney Disease: Serial Biochemistry
• Hematologic and Biochemical Changes in Infectious Diseases

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.